Protagonist Therapeutics Equity 2024

Protagonist Therapeutics Aktienanalyse

What does Protagonist Therapeutics do?

Protagonist Therapeutics Inc is a biopharmaceutical company focused on the development and commercialization of novel peptide therapies. The company was founded in 2002 and is headquartered in Newark, California. The history of Protagonist Therapy began with the discovery of a new type of molecules called peptides, which can be used as potential drugs for various diseases. This discovery was the result of years of research and collaboration between academics and leading pharmaceutical companies. Protagonist Therapeutics' business model is focused on developing and distributing new peptide therapies in the pharmaceutical industry. The company works closely with leading academics and biotechnology companies to advance its research and development projects. Protagonist Therapeutics is divided into several divisions focusing on different therapeutic areas. These include gastrointestinal diseases, immunology, and oncology. Each division works on developing new peptide therapies specifically tailored to their respective therapeutic areas. One example of a product from Protagonist Therapeutics is PTG-300, which was developed for the treatment of iron deficiency anemia. PTG-300 is a synthetic peptide that promotes increased iron uptake in the body to combat iron deficiency. Another product from Protagonist Therapeutics is PTG-200, which was developed for the treatment of inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. PTG-200 is a peptide that blocks the action of certain enzymes that amplify inflammation in the intestine. Overall, Protagonist Therapeutics aims to establish itself as a leading provider of peptide therapies in the pharmaceutical industry. The company has a strong financial foundation, including a successful IPO in 2016, and is continuously working on developing new products to expand and grow the company. Protagonist Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Protagonist Therapeutics's Equity

Protagonist Therapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Protagonist Therapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Protagonist Therapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Protagonist Therapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Protagonist Therapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Protagonist Therapeutics stock

What is the equity of Protagonist Therapeutics this year?

Protagonist Therapeutics has equity of 336.68 M USD this year.

What was the equity of Protagonist Therapeutics compared to the previous year?

The equity of Protagonist Therapeutics has increased/decreased by 56.16% increased compared to the previous year.

What impact does a high equity have on investors of Protagonist Therapeutics?

A high equity is advantageous for investors of Protagonist Therapeutics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Protagonist Therapeutics?

A low equity can be a risk for investors of Protagonist Therapeutics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Protagonist Therapeutics affect the company?

An increase in equity of Protagonist Therapeutics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Protagonist Therapeutics affect the company?

A reduction in equity of Protagonist Therapeutics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Protagonist Therapeutics?

Some factors that can affect the equity of Protagonist Therapeutics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Protagonist Therapeutics so important for investors?

The equity of Protagonist Therapeutics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Protagonist Therapeutics take to change the equity?

To change equity, Protagonist Therapeutics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Protagonist Therapeutics pay?

Over the past 12 months, Protagonist Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Protagonist Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Protagonist Therapeutics?

The current dividend yield of Protagonist Therapeutics is .

When does Protagonist Therapeutics pay dividends?

Protagonist Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Protagonist Therapeutics?

Protagonist Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Protagonist Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Protagonist Therapeutics located?

Protagonist Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Protagonist Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Protagonist Therapeutics from 9/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did Protagonist Therapeutics pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of Protagonist Therapeutics in the year 2023?

In the year 2023, Protagonist Therapeutics distributed 0 USD as dividends.

In which currency does Protagonist Therapeutics pay out the dividend?

The dividends of Protagonist Therapeutics are distributed in USD.